Fabrice Andre,Thomas Filleron,Maud Kamal,Fernanda Mosele,Monica Arnedos,Florence Dalenc,Marie-Paule Sablin,Mario Campone,Hervé Bonnefoi,Claudia Lefeuvre-Plesse,William Jacot,Florence Coussy,Jean-Marc Ferrero,George Emile,Marie-Ange Mouret-Reynier,Jean-Christophe Thery,Nicolas Isambert,Alice Mege,Philippe Barthelemy,Benoit You,Nawale Hajjaji,Ludovic Lacroix,Etienne Rouleau,Alicia Tran-Dien,Sandrine Boyault,Valery Attignon,Pierre Gestraud,Nicolas Servant,Christophe Le Tourneau,Linda Larbi Cherif,Isabelle Soubeyran,Filippo Montemurro,Alain Morel,Amelie Lusque,Marta Jimenez,Alexandra Jacquet,Anthony Gonçalves,Thomas Bachelot,Ivan Bieche

Abstract:Cancer progression is driven in part by genomic alterations 1 . The genomic characterization of cancers has shown interpatient heterogeneity regarding driver alterations 2 , leading to the concept that generation of genomic profiling in patients with cancer could allow the selection of effective therapies 3,4 . Although DNA sequencing has been implemented in practice, it remains unclear how to use its results. A total of 1,462 patients with HER2-non-overexpressing metastatic breast cancer were enroled to receive genomic profiling in the SAFIR02-BREAST trial. Two hundred and thirty-eight of these patients were randomized in two trials (nos. NCT02299999 and NCT03386162) comparing the efficacy of maintenance treatment 5 with a targeted therapy matched to genomic alteration. Targeted therapies matched to genomics improves progression-free survival when genomic alterations are classified as level I/II according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) 6 (adjusted hazards ratio (HR): 0.41, 90% confidence interval (CI): 0.27–0.61, P < 0.001), but not when alterations are unselected using ESCAT (adjusted HR: 0.77, 95% CI: 0.56–1.06, P = 0.109). No improvement in progression-free survival was observed in the targeted therapies arm (unadjusted HR: 1.15, 95% CI: 0.76–1.75) for patients presenting with ESCAT alteration beyond level I/II. Patients with germline BRCA1/2 mutations ( n = 49) derived high benefit from olaparib (g BRCA1 : HR = 0.36, 90% CI: 0.14–0.89; g BRCA2 : HR = 0.37, 90% CI: 0.17–0.78). This trial provides evidence that the treatment decision led by genomics should be driven by a framework of target actionability in patients with metastatic breast cancer.

Genomics to select treatment for patients with metastatic breast cancer